1. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for industry, Bioanalytical method validation, 2001.
2. The European Agency for the Evaluation of Medicinal Products, Pharmacokinetic studies in man, Guideline 3CC3a, 1987. Internet: http://www.emea.europa.eu/htms/human/humanguidelines/efficacy.htm (as of June 23rd, 2009).
3. The European Agency for the Evaluation of Medicinal Products, Conduct of pharmacokinetic studies in animals, Guideline 7AE3a, 1992. Internet: http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol7_en.htm#7a (as of June 23rd, 2009).
4. The European Agency for the Evaluation of Medicinal Products, Committee for Veterinary Medicinal Products, Guidelines for the conduct of pharmacokinetic studies in target animal species, EMEA/CVMP/133/99, London, 2000.
5. Stability of spironolactone in rat plasma: strict temperature control of blood an plasma samples is required in rat pharmacokinetic studies;Tokumura;Biol. Pharm. Bull.,2005